Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001104659-22-118614
Filing Date
2022-11-14
Accepted
2022-11-14 16:30:02
Documents
4
Period of Report
2023-01-12

Document Format Files

Seq Description Document Type Size
1 PRE 14A tm2230379-1_pre14a.htm PRE 14A 245180
2 GRAPHIC lg_vyne-4c.jpg GRAPHIC 28421
3 GRAPHIC tm2230379d1-px_01pagebw.jpg GRAPHIC 518645
4 GRAPHIC tm2230379d1-px_02pagebw.jpg GRAPHIC 382381
  Complete submission text file 0001104659-22-118614.txt   1520339
Mailing Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206, SUITE 301A BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38356 | Film No.: 221386318
SIC: 2834 Pharmaceutical Preparations